Click on a filter below to refine your search. Remove a filter to broaden your search.
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.